MarginsXMarginsX
Home › Markets › Health Care › CYTK

Cytokinetics Incorporated (CYTK)

CYTK trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$53.17
-5.27% on the day
Market cap
$7.4B
Mid cap
Revenue · 2025
$88.0M
+376.6% on 2024
Net income · 2025
-$785.0M
-891.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/0001193125-26-076495-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCYTK on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2004
SEC CIK0001061983
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$88.0M
Net income-$785.0M
Operating income-$612.3M
Net margin-891.6%
Operating margin-695.4%
Revenue growth+376.6%
Cash$122.5M
Total assets$1.4B
P/E (computed)Net income was not positive
P/S (computed)84.1×

Warning signs

Cash runway
4.3 months
$203.4M cash at September 30, 2026
Share count, 1 year
+13.9%
2025-11-03 to 2026-11-02 · +42.1% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$52.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$203.4M cash; operating cash flow -$143.0M a quarter.Report 2026-09-30
Shares outstanding139,303,351 (2026-11-02); 122,264,929 a year earlier; 98,053,647 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-05-07
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Jose, California, United StatesPCAOB Form AP 2026-03-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $52.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$47.6M-$190.1M-$124.0M$203.4M$418.7M$113.3M10-Q 2026-11-04
Q2 2026
2026-06-30
$28.6M-$198.8M-$159.8M$255.3M$275.6M$67.7M10-Q 2026-08-06
Q1 2026
2026-03-31
$19.4M-$206.0M-$145.5M$129.8M$292.0M$105.8M10-Q 2026-05-05
Q4 2025
2025-12-31
$17.8M-$183.0M-$142.7M$122.5M$287.6M$88.0M10-K 2026-02-26
Q3 2025
2025-09-30
$1.9M-$306.2M-$107.5M$225.5M$1.0B$87.2M10-Q 2026-11-04
Q2 2025
2025-06-30
$66.8M-$134.4M-$128.2M$74.9M$609.7M$85.7M10-Q 2026-08-06
Q1 2025
2025-03-31
$1.6M-$161.4M-$131.6M$73.7M$610.1M$19.2M10-Q 2026-05-05
Q4 2024
2024-12-31
$16.9M-$150.0M-$65.6M$94.9M$619.5M$18.5M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-07
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEF 14A2026-04-17

Source: SEC EDGAR submissions feed, 1,005 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.5%
1 month-8.9%
3 months-23.6%
Year to date-11.7%
1 year-14.3%
From 52-week high-35.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
KNSAKiniksa Pharmaceuticals International plc$94.23-2.18%$7.4B
AMRXAmneal Pharmaceuticals Inc.$21.23-0.70%$7.4B
RYTMRhythm Pharmaceuticals Inc.$107.48-6.56%$7.5B
ABVXAbivax SA$83.61-4.53%$7.3B
CORTCorcept Therapeutics Incorporated$69.22-5.10%$7.6B
AXSMAxsome Therapeutics Inc.$137.01-3.30%$7.2B
ALKSAlkermes plc$46.53-1.06%$7.8B
PTGXProtagonist Therapeutics Inc.$124.83-4.67%$8.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier